{{Rsnum
|rsid=1800888
|Gene=ADRB2
|Chromosome=5
|position=148827322
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=T
|GMAF=0.005051
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADRB2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 98.2 | 1.8 | 0.0
| HCB | 99.3 | 0.7 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 99.3 | 0.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 99.1 | 0.9 | 0.0
| MEX | 98.3 | 1.7 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 98.0 | 2.0 | 0.0
| HapMapRevision=28
}}[[rs1800888]], also known as Ile164, is a SNP in the beta 2 adrenergic receptor [[ADRB2]] gene. The [[rs1800888]](T) encodes the much rarer Ile allele.

In a study of 330 patients undergoing percutaneous coronary intervention (PCI), patients carrying a [[rs1800888]](T) allele showed a higher incidence of new acute [[myocardial infarction]] (17.5% vs. 4.5%, p = 0.001), new PCI (37.5% vs. 13.1%, p < 0.0001), and cardiac death (10% vs. 3.1%, p = 0.036). Regression analysis identified [[rs1800888]](T) as an independent predictor of cardiac death (odds ratio 3.731, CI: 1.004 - 13.867, p = 0.049) and an overall major adverse cardiac event (odds ratio 4.1, CI: 1.945 - 8.640, p = 0.0001). 

A replication study was done on a population of 150 patients with [[peripheral artery disease]]. The presence of the [[rs1800888]](T) allele was associated with a higher incidence of acute myocardial infarction (54.5% vs. 25.2%, p = 0.035) or combined events (acute myocardial infarction, PCI, or coronary artery bypass graft) (63.6% vs. 30.9%, p = 0.027).{{PMID|18940527}}

{{omim
|desc=BETA-2-ADRENORECEPTOR AGONIST, REDUCED RESPONSE TO
|id=109690
|rsnum=1800888
|variant=0003
}}

{{ neighbor
| rsid = 1042714
| distance = 412
}}

{{PMID Auto
|PMID=18647184
|Title=Association between polymorphisms in the beta2-adrenoceptor gene and migraine in women
|OA=1
}}

{{PharmGKB
|RSID=rs1800888
|Name_s=ADRB2: 164Thr>Ile; Thr164Ile; 491T>C; Ile164
|Gene_s=ADRB2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:7901205
|Annotation=Receptors containing Ile164 variant showed a substantial decrease in basal and epinephrine-stimulated adenylyl cyclase activities due to defective coupling of the receptor to the stimulatory G protein Gs, and impaired agonist-promoted sequestration. Ile164 also displayed a lower binding affinity for epinephrine as compared with the wild-type ADRB2.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164857064
}}

{{PharmGKB
|RSID=rs1800888
|Name_s=ADRB2: 164Thr>Ile; Thr164Ile; 491T>C; Ile164
|Gene_s=ADRB2
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/adrb2/variant.jsp#ImportantVariantInformationforADRB2-164
|Annotation=Congestive heart failure patients with Ile164 variant were at higher risk for death or heart transplantation in 1 year (event rate 76%) compared to those homozygous for Thr164 while others did not observe this finding. After receiving percutaneous coronary intervention, patients carrying Ile164 variant were 3.7 times more like to have cardiac death and 4.1 times more likely to have a major cardiac adverse event (cardiac death, acute MI, new PCI, CABG, and CHF) than those homozygous for Thr164.
|Drugs=
|Drug Classes=
|Diseases=Cardiomyopathies; Death; Heart Failure; Myocardial Infarction
|Curation Level=In-Depth
|PharmGKB Accession ID=PA164857066
}}

{{PharmGKB
|RSID=rs1800888
|Name_s=ADRB2: 164Thr>Ile; Thr164Ile; 491T>C; Ile164
|Gene_s=ADRB2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:11222464
|Annotation=In vivo studies found that ADRB2 mediated increase in heart rate and contractibility is blunted in subject carrying one allele of Ile164.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164857065
}}

{{PMID Auto
|PMID=21883537
|Title=?(2) -Adrenergic Receptor Thr164Ile Polymorphism, Blood Pressure and Ischaemic Heart Disease in 66,750 Individuals
}}

{{ClinVar
|rsid=1800888
|Reversed=0
|FwdREF=C
|FwdALT=T
|REF=C
|ALT=T
|RSPOS=148206885
|CHROM=5
|GMAF=0.005
|dbSNPBuildID=89
|SSR=0
|SAO=1
|VP=0x050378000000040517110100
|GENEINFO=ADRB2:154
|GENE_NAME=ADRB2
|GENE_ID=154
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000005.9:g.148206885C>T
|CLNORIGIN=1
|CLNSIG=6
|Tags=PM;TPA;PMC;S3D;SLO;VLD;HD;GNO;KGPhase1;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.9949; 0.005051
|CLNACC=RCV000019320.1
|CLNDBN=Beta-2-adrenoreceptor agonist, reduced response to
|CLNDSDB=MedGen
|CLNDSDBID=C1862282
|CLNSRC=OMIM Allelic Variant
|CLNSRCID=109690.0003
|COMMON=1
|Disease=Beta-2-adrenoreceptor agonist
}}

{{PMID Auto
|PMID=15726497
|Title=Gene-environment interaction effects on the development of immune responses in the 1st year of life.
|OA=1
}}

{{PMID Auto
|PMID=16600026
|Title=Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway.
|OA=1
}}

{{PMID Auto
|PMID=16935688
|Title=Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study.
}}

{{PMID Auto
|PMID=18709160
|Title=Interactions between glutathione S-transferase P1, tumor necrosis factor, and traffic-related air pollution for development of childhood allergic disease.
|OA=1
}}

{{PMID Auto
|PMID=19131662
|Title=A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients.
|OA=1
}}

{{PMID Auto
|PMID=19190821
|Title=Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women.
|OA=1
}}

{{PMID Auto
|PMID=19284637
|Title=Polymorphisms in the ADRB2 gene and Graves disease: a case-control study and a meta-analysis of available evidence.
|OA=1
}}

{{PMID Auto
|PMID=19330901
|Title=Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study.
|OA=1
}}

{{PMID Auto
|PMID=19559392
|Title=A candidate gene association study of 77 polymorphisms in migraine.
|OA=1
}}

{{PMID Auto
|PMID=19779622
|Title=No consistent effect of ADRB2 haplotypes on obesity, hypertension and quantitative traits of body fatness and blood pressure among 6,514 adult Danes.
|OA=1
}}

{{GET Evidence
|gene=ADRB2
|aa_change=Thr164Ile
|aa_change_short=T164I
|impact=pharmacogenetic
|qualified_impact=Low clinical importance, Uncertain pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1800888
|overall_frequency_n=118
|overall_frequency_d=10758
|overall_frequency=0.0109686
|n_genomes=2
|n_genomes_annotated=0
|n_haplomes=2
|n_articles=2
|n_articles_annotated=2
|qualityscore_in_silico=!
|qualitycomment_in_silico=Y
|qualityscore_in_vitro=4
|qualitycomment_in_vitro=Y
|qualityscore_case_control=0
|qualitycomment_case_control=Y
|qualityscore_severity=0
|qualitycomment_severity=Y
|qualityscore_treatability=0
|qualitycomment_treatability=Y
|gene_in_genetests=Y
|in_omim=Y
|genetests_testable=Y
|nblosum100=3
|autoscore=4
|webscore=N
|n_web_uneval=10
|variant_evidence=0
|clinical_importance=0
|summary_short=This rare variant in β2-Adrenoceptor has only reported heterozygously (in 2-4% of the population) and strongly decreases the protein’s responsiveness to inducing compounds (agonists). Carriers of this variant are less sensitive to induction of increased heart rate, heart contraction, and vasodilation by β-AR agonists. Mixed data suggests that this variant does not have a significant impact on hypertension or heart disease. It may affect responsiveness to beta blocker drugs.
}}

{{PMID Auto
|PMID=23463918
|Title=Childhood lung function and the association with β2-adrenergic receptor haplotypes
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}